The first patient has been dosed in a Phase 1 trial assessing Syros Pharmaceuticals' investigative therapy SY-1365 in patients with advanced solid tumors, the company announced. The trial will particularly enroll participants with cancers that are highly dependent on transcription processes to thrive, including ovarian cancer, triple-negative breast cancer, and small cell lung cancer. “SY-1365 represents a promising new approach for treating a number of aggressive cancers that have eluded treatment with other targeted approaches,” Anthony W. Tolcher, MD, director of clinical research at South Texas Accelerated Research Therapeutics (START) and a clinical investigator in the trial, said in a press release. “Certain cancers are particularly dependent on high expression of transcription factors for their growth and survival, and SY-1365 has shown substantial anti-tumor activity in preclinical models of these cancers," he said. "We’re pleased to have enrolled the first patient in this clinical trial and look forward to further investigating SY-1365 for patients with these difficult-to-treat solid tumors.” While the transcription process — the production of a protein from a gene — is universal to all cells and tissues, studies have shown that some genes are especially sensitive to inhibiting transcription. The control of gene transcription involves a set of cyclin-dependent kinases (CDK), including CDK7, which are critical elements in the transcription process. Therefore, inhibiting these proteins could hold promise in the treatment of certain cancers highly dependent on transcription processes.